Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients

NEXT STORY
Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period – by PMI
PREV STORY
ABT AWARDED $267 MILLION EXTENSION FOR PMI VECTORLINK PROJECT TO CONTROL MALARIA IN 26 COUNTRIES
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab

author_avatar
NASDAQ Market News

The US Oncology Network Selects Myriad Genetics as Preferred Provider for Hereditary Cancer Testing

THE WOODLANDS, Texas and SALT LAKE CITY, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Myriad ...

author_avatar
NASDAQ Market News

AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis

author_avatar
NASDAQ Market News